RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07032532, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients must have histologically confirmed peripheral T-cell lymphoma. Eligible histological subtypes are restricted to the following:

    Inclusion criterion 4

  3. Prior treatment with a JAK or STAT3 inhibitor.

    Exclusion criterion 6

    Prior treatment with any onco-immunotherapy in 28 days.

    Exclusion criterion 7

    Patients currently receiving (or unable to stop use at least 14 days prior to receiving the first dose) medications or herbal supplements known to be Potent inhibitors or inducers of CYP3A.

    Exclusion criterion 9

  4. ECOG performance status 0-2 with no deterioration over the previous 2 weeks.

    Inclusion criterion 2

  5. Patients must have measurable disease according to the 2014 Lugano classification.

    Inclusion criterion 9

  6. Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or nonmelanomatous skin cancer.

    Exclusion criterion 15

  7. Women who are breast feeding or pregnant.

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07032532, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male and female ≥ 18 years old.
  • ECOG performance status 0-2 with no deterioration over the previous 2 weeks.
  • Predicted life expectancy ≥ 12 weeks.
  • Patients must have histologically confirmed peripheral T-cell lymphoma. Eligible histological subtypes are restricted to the following:
  • PTCL, not otherwise specified (PTCL, NOS) (the proportion of PTCL-NOS subtype will not exceed 30% of all enrolled)
  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Follicular T cell lymphoma
  • PTCL with T follicular helper (TFH) phenotype
  • Patients must have measurable disease according to the 2014 Lugano classification.
  • Patients must be treatment naïve with no prior systemic treatment for T-cell lymphoma.
  • Adequate bone marrow reserve and organ system functions.
  • Willing to comply with contraceptive restrictions.

Exclusion Criteria:

  • Intervention with any of the following:
  • Any investigational anti-cancer agents or study anti-cancer drugs from a previous clinical study.
  • Any cytotoxic chemotherapy from a previous treatment regimen.
  • Corticosteroids at dosages equivalent to prednisone > 40 mg/day within 7 days.
  • Major surgery procedure, or significant traumatic injury within 4 weeks.
  • Prior treatment with a JAK or STAT3 inhibitor.
  • Prior treatment with any onco-immunotherapy in 28 days.
  • Live vaccines within 28 days.
  • Patients currently receiving (or unable to stop use at least 14 days prior to receiving the first dose) medications or herbal supplements known to be Potent inhibitors or inducers of CYP3A.
  • Central nervous system or leptomeningeal lymphoma.
  • Past medical history of pneumonitis, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
  • Patients with disease condition which requires the treatment of immunosuppressants, biologics, or NSAID.
  • Active infections
  • Clinically significant cardiac disorders or abnormalities. Acute thrombotic diseases within 90 days.
  • Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
  • Gastrointestinal disorders that is inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of golidocitinib.
  • History of hypersensitivity to active or inactive excipients of golidocitinib or drugs with a similar chemical structure or class.
  • Women who are breast feeding or pregnant.

Quoted from ClinicalTrials.gov, NCT07032532, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07032532, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07032532